Search research articles
Contact Us
Filters
Showing results (91-100 of 120) with videos related to
Page
of 12
Sort By:
NPJ Digital Medicine
|
December 8, 2025
Explainable AI-driven precision clinical trial enrichment: demonstration of the NetraAI platform with a phase II depression trial
Joseph Geraci, Bessi Qorri, Mike Tsay, et al.
BMJ Open
|
June 16, 2026
Efficacy and safety of long-acting injectable paliperidone palmitate 1-month and 3-month formulations in the maintenance treatment of schizophrenia: a single-arm, open-label, interventional study in Rwandan healthcare settings
Rutakayile Bizoza, Jordy Mehawej, Emmanuel Musoni-Rwililiza, et al.
Schizophrenia Research. Cognition
|
September 16, 2022
Dispersion of cognitive performance test scores on the MATRICS Consensus Cognitive Battery: A different perspective
David J Williamson, Keith H Nuechterlein, Todd Tishler, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Drug Development
Joseph Geraci, Patrick P O'Keefe, Bessi Qorri, et al.
Clinical Schizophrenia & Related Psychoses
|
February 23, 2013
Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease
Joan Amatniek, Carla M Canuso, Stephen I Deutsch, et al.
Acta Psychiatrica Scandinavica
|
November 29, 2020
Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression
Ibrahim Turkoz, Larry Alphs, Jaskaran Singh, et al.
Pharmacogenetics and Genomics
|
November 16, 2016
Genome-wide association study of paliperidone efficacy
Qingqin Li, Nathan E Wineinger, Dong-Jing Fu, et al.
The Journal of Clinical Psychiatry
|
January 7, 2015
Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder
Dong-Jing Fu, Ibrahim Turkoz, R Bruce Simonson, et al.
The American Journal of Psychiatry
|
August 3, 2004
Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial
Marc Bourgeois, Joel Swendsen, Frederick Young, et al.
Innovations in Clinical Neuroscience
|
July 25, 2013
Study Site Experiences and Attitudes Toward Prospective Assessments of Suicidal Ideation and Behavior in Clinical Trials: Results of an Internet-based Survey
Michelle Stewart, Adam Butler, Larry Alphs, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 120) with videos related to
Sort By:
Page
of 12
NPJ Digital Medicine
|
December 8, 2025
Explainable AI-driven precision clinical trial enrichment: demonstration of the NetraAI platform with a phase II depression trial
Joseph Geraci, Bessi Qorri, Mike Tsay, et al.
BMJ Open
|
June 16, 2026
Efficacy and safety of long-acting injectable paliperidone palmitate 1-month and 3-month formulations in the maintenance treatment of schizophrenia: a single-arm, open-label, interventional study in Rwandan healthcare settings
Rutakayile Bizoza, Jordy Mehawej, Emmanuel Musoni-Rwililiza, et al.
Schizophrenia Research. Cognition
|
September 16, 2022
Dispersion of cognitive performance test scores on the MATRICS Consensus Cognitive Battery: A different perspective
David J Williamson, Keith H Nuechterlein, Todd Tishler, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Drug Development
Joseph Geraci, Patrick P O'Keefe, Bessi Qorri, et al.
Clinical Schizophrenia & Related Psychoses
|
February 23, 2013
Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease
Joan Amatniek, Carla M Canuso, Stephen I Deutsch, et al.
Acta Psychiatrica Scandinavica
|
November 29, 2020
Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression
Ibrahim Turkoz, Larry Alphs, Jaskaran Singh, et al.
Pharmacogenetics and Genomics
|
November 16, 2016
Genome-wide association study of paliperidone efficacy
Qingqin Li, Nathan E Wineinger, Dong-Jing Fu, et al.
The Journal of Clinical Psychiatry
|
January 7, 2015
Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder
Dong-Jing Fu, Ibrahim Turkoz, R Bruce Simonson, et al.
The American Journal of Psychiatry
|
August 3, 2004
Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial
Marc Bourgeois, Joel Swendsen, Frederick Young, et al.
Innovations in Clinical Neuroscience
|
July 25, 2013
Study Site Experiences and Attitudes Toward Prospective Assessments of Suicidal Ideation and Behavior in Clinical Trials: Results of an Internet-based Survey
Michelle Stewart, Adam Butler, Larry Alphs, et al.
Page
of 12